SynthesisJournal of Zhejiang University. Science. B2018
Radiofrequency ablation versus hepatic resection for breast cancer liver metastasis: a systematic review and meta-analysis.
Synthesis in Journal of Zhejiang University. Science. B, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Electrocoagulation for liver metastases.The Cochrane database of systematic reviews · 2021Pooled it
- Survival Benefit of Surgical Treatment Added Into Systemic Treatment for Isolated Breast Cancer Liver Metastases: A Systematic Review and Meta-Analysis.Frontiers in surgery · 2021Pooled it
- Predictive factors of improved postoperative results after surgery for patients with hepatocellular carcinoma: a retrospective study.Archives of medical science : AMS · 2026Article
- Oligometastatic breast cancer and metastasis-directed treatment: an aggressive multimodal approach to reach the cure.Therapeutic advances in medical oncology · 2023Review
- Different risk and prognostic factors for liver metastasis of breast cancer patients withFrontiers in oncology · 2023Article
- Retraction Note to: Radiofrequency ablation versus hepatic resection for breast cancer liver metastasis: a systematic review and meta-analysis.Journal of Zhejiang University. Science. B · 2022Article
- A Novel Nomogram Model to Predict the Recurrence-Free Survival and Overall Survival of Hepatocellular Carcinoma.Frontiers in oncology · 2022Article
- Does hepatectomy improve outcomes of breast cancer with liver metastasis? A nationwide analysis of real-world data in Taiwan.PloS one · 2022Article
- The global status of research in breast cancer liver metastasis: a bibliometric and visualized analysis.Bioengineered · 2021Article
- Formosanin C promotes the curative efficacy of ultrasound-guided radiofrequency ablation in a mouse model of breast cancer.Oncology letters · 2021Article
- Breast cancer liver metastasis: current and future treatment approaches.Clinical & experimental metastasis · 2021Review
- A systematic review and meta-analysis of radio frequency ablation and routine resection in the treatment of small hepatocellular carcinoma.Journal of gastrointestinal oncology · 2021Article
- Advanced Techniques in the Percutaneous Ablation of Liver Tumours.Diagnostics (Basel, Switzerland) · 2021Review
- Genome‑wide copy number analysis of circulating tumor cells in breast cancer patients with liver metastasis.Oncology reports · 2020Article
- The role of surgical intervention for isolated breast cancer liver metastasis: Results of case-control study with comparison to medical treatment.Cancer medicine · 2020Article
- Oligometastatic Breast Cancer: Is This a Curable Entity? A Contemporary Review of the Literature.Current oncology reports · 2020Review
- RIG-I Promotes Cell Death in Hepatocellular Carcinoma by Inducing M1 Polarization of Perineal Macrophages Through the RIG-I/MAVS/NF-κB Pathway.OncoTargets and therapy · 2020Article
- Transarterial Yttrium-90 Glass Microsphere Radioembolization of Chemotherapy-Refractory Breast Cancer Liver Metastases: Results of a Single Institution Retrospective Study.Advances in radiation oncologyArticle
- Association between social health status and depressive symptoms among community-dwelling elderly adults in Zhejiang Province, China.Journal of Zhejiang University. Science. BArticle
Corrections and comments
- Retraction · 2022-04-30Error in Analyses · Error in Methods · Unreliable Results and/or Conclusions ·
- Retracted
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the comparative therapeutic efficacy of radiofrequency ablation (RFA) and hepatic resection (HR) for breast cancer liver metastases (BCLMs).
methodsStudies that had examined the outcomes for both RFA and HR for BCLM were identified by searching the electronic databases PubMed, EMBASE, and the Cochrane Library. Pooled analyzes of the overall survival (OS), disease-free survival (DFS), and short-term outcomes of BCLM were performed.
resultsPatients with BCLM gained many more survival benefits from HR than from RFA with regard to the 3-year OS rate (combined odds ratio (OR) 0.41, 95% confidence interval (CI) 0.29-0.59, P<0.001), 5-year OS rate (combined OR 0.38, 95% CI 0.32-0.46, P<0.001), 3-year DFS (combined OR 0.36, 95% CI 0.27-0.49, P<0.001), and 5-year DFS (combined OR 0.51, 95% CI 0.40-0.66, P<0.001). RFA had fewer postoperative complications (combined OR 0.30, 95% CI 0.20-0.44, P<0.001) and shorter hospital stays (combined OR -9.01, 95% CI -13.49-4.54, P<0.001) than HR.
conclusionsHR takes precedence over RFA in the treatment of patients with BCLM, considering the better survival rate. RFA gives rise to fewer complications and can be carried out with a shorter hospital stay, compared to HR. RFA should be reserved for patients who are not optimum candidates for resection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.